Management and outcomes of advanced hemangioendothelioma at a medical oncology clinic in an Indian tertiary care center

AIM: Hemangioendotheliomas (HEs) are malignant vascular tumors with sparse descriptions in literature owing to their rarity. STUDY DESIGN: Ours is a retrospective study among patients of advanced HEs registered between September 2015 and April 2021. RESULTS: There were 13 patients with median age 34...

Descripción completa

Detalles Bibliográficos
Autores principales: Tansir, Ghazal, Rastogi, Sameer, Barwad, Adarsh, Yadav, Rajni, Shamim, Shamim Ahmed, Dhamija, Ekta, Pandey, Rambha, Garg, Rakesh, Shrivastava, Shakti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979162/
https://www.ncbi.nlm.nih.gov/pubmed/36874373
http://dx.doi.org/10.2144/fsoa-2021-0132
Descripción
Sumario:AIM: Hemangioendotheliomas (HEs) are malignant vascular tumors with sparse descriptions in literature owing to their rarity. STUDY DESIGN: Ours is a retrospective study among patients of advanced HEs registered between September 2015 and April 2021. RESULTS: There were 13 patients with median age 34.6 (range: 4–69 years), male preponderance (69%) and predominant subtype of epithelioid HE (76.9%). Common primary sites were viscera (46.2%) and bone (30.8%). Tyrosine kinase inhibitors (TKIs) yielded objective responses in 30% patients whereas chemotherapy only produced disease stabilization in 7.7%. CONCLUSION: We recognize an aggressive subset of HEs with manifestations such as acute liver failure and splenic rupture. Currently no biomarkers predict the efficacy of TKIs over chemotherapy; however, TKIs showed promising outcomes in this series.

Ejemplares similares